Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Natera

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.

Investors Business Daily

Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'

Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening.

Investors Business Daily

Analysts reset price target on recent Stanley Druckenmiller stock pick

Here’s what could be next for a company that surged more than 150% last year.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Stanley Druckenmiller makes big bet on high-tech healthcare

The billionaire investor takes a sizable position in this healthcare services provider.

The Street

Cathie Wood Stock Poised To Extend Gains

A Cathie Wood ARK Invest ETF owns over $46 million of this biotech stock. The stock is climbing ahead of its earnings report.

Investors Business Daily

DNA Testing Stock Taps AI Amid 85% Surge

Natera is in a consolidation with a buy point of 117.23.

Investors Business Daily

Dow Jones Rallies 100 Points, Led By McDonald's, 3M; Tech Giants Micron, Broadcom, Nvidia Show Strength

The Nasdaq composite faded off highs in the stock market today, but TSMC held a bullish gain after reporting strong sales in April.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise

Natera stock rocketed to a three-year high Friday, buoyed by a "robust beat-and-raise" and its first-ever quarter of positive cash flow.

Investors Business Daily

Genetic Testing Stock Nears Buy Point After Earnings Gap-Up And 45% Gain

Natera stock has outperformed the S&P 500 year to date and is near a buy point after earnings. Natera provides genetic testing services.

Investors Business Daily

Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle

Natera stock surged Wednesday after a jury said the company must pay Ravgen $57 million in a patent lawsuit — far below expectations.

Investors Business Daily

S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record December

A pullback or moderation in the small-cap rally should come as no surprise.

Investors Business Daily

Natera Stock Showing Rising Market Leadership, Earns 82 RS Rating

A Relative Strength Rating upgrade for Natera shows improving technical performance.

Investors Business Daily

Bay Area tech and biotech layoffs worsen, Microsoft slashes more jobs

Tech and biotech layoffs have worsened in the Bay Area, a fresh round of cutbacks resulting from job cuts at tech titan Microsoft and genetic testing firm Natera, according to official state government filings.

Tribune News Service

Why Natera Stock Is Leading Its Industry Group With A 17% Jump Today

Natera stock broke definitively above its 200-day line Thursday after Medicare opted to reimburse for its breast cancer test.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

This Unpopular Move Could Save Invitae

Offloading a recent acquisition could accelerate the path to profitability – or an acquisition.

StockNews.com

This Diagnostic Testing Company Down 60% - Time to Buy?

Despite witnessing double-digit revenue growth in the last reported quarter Natera Inc. (NTRA) stock has plunged nearly 60% year-to-date. So, let’s evaluate if it is worth buying the stock now. Read on.

Benzinga

8 Analysts Have This to Say About Natera

Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:

Benzinga

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

Natera Inc (NASDAQ:NTRA) generated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million. Product revenues were $190.0 million, an increase of 57.8%. The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21. The gross profit margin compressed to 46.8% from 56.1%, primarily due…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Earnings Preview For Natera

Natera (NASDAQ:NTRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Natera will report an earnings per share (EPS) of $-1.48.

Benzinga

Analyst Ratings for Natera

Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga

$100 Invested In Natera 5 Years Ago Would Be Worth This Much

Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 22.16% on an annualized basis.

Benzinga

Check Out What Whales Are Doing With NTRA

A whale with a lot of money to spend has taken a noticeably bearish stance on Natera. Looking at options history for Natera (NASDAQ:NTRA) we detected 39 strange trades.

Benzinga

So What's Happening With Natera Shares?

Natera Inc (NASDAQ: NTRA) shares are trading lower by 31.2% at $37.66 after Hindenburg Research issued a short report on the stock.

Benzinga

3 Reasons Why This Natera Analyst Says The Selloff Is Overdone

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company following a Hindenburg Research short

1 2

People

Stanley Druckenmiller

33 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

354 stories

Gap

347 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.